EU-godkännande av nytt läkemedel för behandling av njurcancer
European Commission approves Ipsen’s Cabometyx™ (cabozantinib) Tablets for the treatment of advanced renal cell carcinoma (RCC) in adults following prior vascular endothelial growth factor (VEGF)-targeted therapy· Cabometyx™ (cabozantinib) is the first and only targeted therapy to improve Overall Survival (OS), Objective Response Rate (ORR), and Progression Free Survival (PFS) in RCC in METEOR randomized Phase 3 trial · Cabometyx™ (cabozantinib) improves OS across all evaluated patient subgroups · Cabometyx™ (cabozantinib) has a unique mechanism of action with the potential to